ALMS Stock Summary and Trading Ideas (Alumis | NASDAQ:ALMS)

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Alumis trades on the NASDAQ stock market under the symbol ALMS.

As of June 12, 2026, ALMS stock price climbed to $24.15 with 2,151,091 million shares trading.

ALMS has a beta of 0.76, meaning it tends to be less sensitive to market movements. ALMS has a correlation of 0.01 to the broad based SPY ETF.

ALMS has a market cap of $3.08 billion. This is considered a Mid Cap stock.

Last quarter Alumis reported $2 million in Revenue and -$.74 earnings per share. This fell short of revenue expectation by $-919,320 and exceeded earnings estimates by $.04.

The top ETF exchange traded funds that ALMS belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

ALMS has outperformed the market in the last year with a price return of +634.0% while the SPY ETF gained +24.6%. However, in the short term, ALMS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -8.3% vs +9.9% return in SPY. But in the last 2 weeks, ALMS shares have fared better than the market returning +12.9% compared to SPY -1.7%.

ALMS support price is $20.08 and resistance is $21.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALMS shares will trade within this expected range on the day.